Long-term fenofibrate therapy did not reduce major coronary events but may reduce total CVD events in type 2 diabetes mellitus: COMMENTARY

McQueen, Matthew
May 2006
ACP Journal Club;May/Jun2006, Vol. 144 Issue 3, p64
Academic Journal
The article presents comments of the author on a study which found that long-term fenofibrate therapy did not reduce major coronary events but may reduce total CVD events in type 2 diabetes mellitus. It is disappointing that fenofibrate did not reduce fatal myocardial infarcation or coronary heart disease mortality in patients with type 2 diabetes mellitus. In the increasing, worldwide challenge to reduce morbidity and mortality from diabetes, the FIELD study shows that fenofibrate may have beneficial effects on microvascular disease and reduce risk for macrovascular events while improving lipid profiles.


Related Articles

  • COMMENTARY: Review: Pioglitazone does not reduce risk for mortality or cardivascular events in type 2 diabetes. Smith, Donald // ACP Journal Club;Mar/Apr2007, Vol. 146 Issue 2, p40 

    The article presents the author's views about a study which states that pioglitazone does not reduce risk for mortality or cardivascular events in type 2 diabetes. The study lasted for 35 months and included patients with diabetes and macrovascular disease at baseline. Pioglitazone did not lower...

  • ISCHAEMIC HEART DISEASE. Gorog, Diana; Kapur, Akhil; Khan, Masood; Lindsay, Alistair; Sharp, Andrew // Heart;Mar2006, Vol. 92 Issue 3, p430 

    The article presents a collection of research studies on ischemic heart disease published in various periodicals. The use of rescue angioplasty after failed thrombolytic therapy for acute myocardial infarction has been assessed. Researchers examine the effects of long-term fenofibrate therapy on...

  • Heart in Diabetes: A Microvascular Disease. LAAKSO, MARKKU // Diabetes Care;May2011 Supplement 2, Vol. 34, pS145 

    The article looks at the microvascular component of heart disease in people with diabetes. In people with type 2 diabetes, macrovascular complications like coronary artery disease (CAD), stroke and peripheral vascular disease are increased by two- to four-fold. Four damaging pathways are...

  • Retrospective analysis of cardiovascular outcomes in patients with type 2 diabetes mellitus after the first acute myocardial infarction. Mozejko-Pastewka, B.; Taton, J.; Haczynski, J.; Strojek, K.; Ametov, A. S.; Milicevic, Z. // Acta Diabetologica;Dec2003 Supplement 2, Vol. 40, ps354 

    We retrospectively analyzed survival in patients with type 2 diabetes mellitus (DM) after first acute myocardial infarction (AMI). The study was conducted in 5 sites in Poland and involved 521 patients who survived more than 30 days after AMI. In the 5-year period after the acute event, we...

  • Cardiovascular Events After Bariatric Surgery in Obese Subjects With Type 2 Diabetes. ROMEO, STEFANO; MAGLIO, CRISTINA; BURZA, MARIA ANTONELLA; PIRAZZI, CARLO; SJÖHOLM, KAJSA; JACOBSON, PETER; SVENSSON, PER-ARNE; PELTONEN, MARKKU; SJÖSTRÖM, LARS; CARLSSON, LENA M.S. // Diabetes Care;Dec2012, Vol. 35 Issue 12, p2613 

    OBJECTIVE-Obese individuals with type 2 diabetes have an increased risk of cardiovascular disease. The effect of bariatric surgery on cardiovascular events in obese individuals with type 2 diabetes remains to be determined. The Swedish Obese Subjects (SOS) study is a prospective, controlled...

  • Silent myocardial infarction and its prognosis in a community-based cohort of Type 2 diabetic patients: the Fremantle Diabetes Study Silent myocardial infarction in diabetes. Davis, T. M. E.; Fortun, P.; Mulder, J.; Davis, W. A.; Bruce, D. G. // Diabetologia;Mar2004, Vol. 47 Issue 3, p395 

    Aims/hypothesis. Our study investigated the prognosis of Type 2 diabetic patients with silent myocardial infarction in a community-based cohort. Methods. We analysed data from 1269 patients with Type 2 diabetes mellitus from a community-based observational study of diabetes care, control and...

  • Is treatment of hypertension with acetylcholine esterase inhibitors (ACEIs) superior to other antihypertensives in preventing significant cardiovascular events and death in patients with type 2 diabetes? McConaghy, John R. // Journal of Family Practice;Nov2000, Vol. 49 Issue 11, p980 

    The article presents a study which examined whether the treatment of hypertension with acetylcholine esterase inhibitors (ACEI) is superior to other antihypertensives in the prevention of significant cardiovascular events and death in diabetics. The study recommended that lowering blood pressure...

  • Serum Zinc Level and Coronary Heart Disease Events in Patients With Type 2 Diabetes. Soinio, Minna; Marniemi, Jukka; Laakso, Markku; Pyörälä, Kalevi; Lehto, Seppo; Rönnemaa, Tapani // Diabetes Care;Mar2007, Vol. 30 Issue 3, p523 

    OBJECTIVE -- Low serum zinc level may predispose nondiabetic subjects to cardiovascular diseases. Our aim was to investigate whether serum zinc level predicts coronary heart disease (CHD) events in subjects with type 2 diabetes RESEARCH DESIGN AND METHODS -- The original study population...

  • Oxidation Type 2 Diabetes, and Coronary Heart Disease: A Complex Interaction. Stranges, Saverio; Dorn, Joan M.; Donahue, Richard P.; Browne, Richard W.; Freudenheim, Jo L.; Hovey, Kathleen M.; Trevisan, Maurizio // Diabetes Care;Sep2008, Vol. 31 Issue 9, p1864 

    OBJECTIVE-- The purpose of this study was to analyze the interrelationship among oxidation, myocardial infarction (MI), and type 2 diabetes in a population-based case-control study of MI. RESEARCH DESIGN AND METHODS-- Participants were 1,709 individuals from western New York: 257 women and men...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics